We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

55 hedge funds and large institutions have $18M invested in Matinas BioPharma in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

10% more funds holding

Funds holding: 50 → 55 (+5)

0.01% more ownership

Funds ownership: 0.25% → 0.26% (+0.01%)

16% less capital invested

Capital invested by funds: $21.5M → $18M (-$3.49M)

Holders
55
Holders Change
+5
Holders Change %
+10%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
9
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
+$279K
2
SIG
Sargent Investment Group
Maryland
+$194K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$109K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$77.8K
5
Renaissance Technologies
Renaissance Technologies
New York
+$26.6K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$51.7K
2
VF
Virtu Financial
New York
-$51.6K
3
PAG
Private Advisor Group
New Jersey
-$47.1K
4
IIA
IPG Investment Advisors
California
-$45K
5
Jane Street
Jane Street
New York
-$22.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
26
Osaic Holdings
Arizona
$21K – – –
Renaissance Technologies
27
Renaissance Technologies
New York
$21K +$26.6K +676 New
DAS
28
Dynamic Advisor Solutions
Arizona
$19K – – –
MA
29
MONECO Advisors
Connecticut
$19K – – –
Commonwealth Equity Services
30
Commonwealth Equity Services
Massachusetts
$18K – – –
VF
31
Virtu Financial
New York
$17K -$51.6K -1,314 -71%
Victory Capital Management
32
Victory Capital Management
Texas
$15K -$3.93K -100 -17%
GAA
33
Global Assets Advisory
Florida
$14K +$14.3K +365 New
Morgan Stanley
34
Morgan Stanley
New York
$13K -$15.7K -399 -50%
Wells Fargo
35
Wells Fargo
California
$13K +$118 +3 +0.7%
Citadel Advisors
36
Citadel Advisors
Florida
$13K +$16.3K +416 New
TRCT
37
Tower Research Capital (TRC)
New York
$12K +$15.2K +387 New
RPC
38
Rossmore Private Capital
Connecticut
$11K – – –
MFG
39
Magnus Financial Group
New York
$10K – – –
CFG
40
Cooper Financial Group
California
$9K +$10.9K +278 New
SG
41
StoneX Group
New York
$8.84K +$10.9K +278 New
CG
42
Clarus Group
Texas
$8K – – –
HF
43
HRT Financial
New York
$8K +$10.2K +260 New
JWCA
44
J.W. Cole Advisors
Florida
$7K – – –
BJL
45
Brighton Jones LLC
Washington
$6K – – –
CFS
46
CRA Financial Services
New Jersey
$6K – – –
FAIM
47
Financial Advocates Investment Management
Washington
$6K – – –
SW
48
SlateStone Wealth
Florida
$6K +$7.86K +200 New
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$5K +$196 +5 +3%
HFM
50
Hartford Financial Management
Connecticut
$2K – – –
1
2
3

MTNB Hedge Fund Activity: Q3 2022 in Review

55 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2022, worth a combined $18M — down 16% from $21.5M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new MTNB positions and 4 closed out — a net gain of 5 holders — while 9 added to existing stakes and 7 trimmed.

The largest buyer was LPL Financial, adding an estimated $279K. The largest seller was BlackRock, cutting an estimated $51.7K.

  • 55 institutional investors held Matinas BioPharma (MTNB) as of Q3 2022, up from 50 in Q2 2022.
  • Funds reported $18M of Matinas BioPharma stock for Q3 2022, down 16% quarter-over-quarter.
  • 9 funds opened new Matinas BioPharma positions in Q3 2022 and 4 closed out, a net change of +5 holders.
  • The largest Matinas BioPharma buyer in Q3 2022 was LPL Financial, an estimated $279K added.
  • The largest Matinas BioPharma seller in Q3 2022 was BlackRock, an estimated $51.7K sold.

Based on aggregated 13F filings for Q3 2022.